GOCON Biotech

GoCon Biotech is a clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan, focused on revolutionizing the delivery of macromolecular drugs. The company leverages its proprietary G-Smart platform, an innovative oral delivery technology designed to enable the systemic absorption of peptides and proteins through the gastrointestinal tract. This platform aims to replace traditional injections with oral formulations, significantly improving patient adherence and quality of life. GoCon's lead program, GC-101, is an oral GLP-1 receptor agonist currently in clinical development for the treatment of type 2 diabetes and obesity. Additionally, the company is advancing a pipeline of other oral peptide candidates, including treatments for osteoporosis. Through its cutting-edge delivery solutions, GoCon Biotech addresses significant unmet needs in chronic disease management.